Insider Buying: Immunocore Holdings plc (NASDAQ:IMCR) Director Acquires 807,338 Shares of Stock

Immunocore Holdings plc (NASDAQ:IMCR) Director Bros. Advisors Lp Baker purchased 807,338 shares of the stock in a transaction dated Monday, March 17th. The stock was purchased at an average price of $29.72 per share, for a total transaction of $23,994,085.36. Following the completion of the acquisition, the director now directly owns 2,144,060 shares in the company, valued at approximately $63,721,463.20. This represents a 60.40 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website.

Immunocore Trading Up 1.2 %

NASDAQ:IMCR traded up $0.33 during trading hours on Wednesday, reaching $28.71. 139,809 shares of the company were exchanged, compared to its average volume of 434,862. The stock has a 50 day simple moving average of $30.03 and a 200 day simple moving average of $31.22. Immunocore Holdings plc has a 52-week low of $27.19 and a 52-week high of $66.00. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. The firm has a market cap of $1.44 billion, a price-to-earnings ratio of -30.22 and a beta of 0.79.

Analyst Upgrades and Downgrades

IMCR has been the subject of a number of research reports. Morgan Stanley reaffirmed an “equal weight” rating and set a $35.00 price target on shares of Immunocore in a research report on Friday, March 7th. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price target on shares of Immunocore in a research report on Wednesday, March 12th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $71.00 price objective on shares of Immunocore in a research note on Wednesday, March 12th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $65.64.

Hedge Funds Weigh In On Immunocore

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Wellington Management Group LLP grew its holdings in Immunocore by 10.5% during the 3rd quarter. Wellington Management Group LLP now owns 7,048,833 shares of the company’s stock worth $219,430,000 after acquiring an additional 668,382 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its stake in shares of Immunocore by 3.1% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 6,700,208 shares of the company’s stock worth $197,657,000 after acquiring an additional 200,373 shares in the last quarter. FMR LLC grew its position in Immunocore by 0.5% during the 3rd quarter. FMR LLC now owns 4,836,040 shares of the company’s stock worth $150,546,000 after purchasing an additional 23,436 shares in the last quarter. Primecap Management Co. CA lifted its position in shares of Immunocore by 8.0% in the fourth quarter. Primecap Management Co. CA now owns 2,668,550 shares of the company’s stock worth $78,722,000 after purchasing an additional 196,530 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in Immunocore by 1.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,187,530 shares of the company’s stock valued at $64,533,000 after purchasing an additional 29,832 shares during the last quarter. 84.50% of the stock is owned by institutional investors and hedge funds.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.